Long-Term Use of Tedizolid in Osteoarticular Infections: Benefits among Oxazolidinone Drugs
暂无分享,去创建一个
Á. Soriano | M. Pedro-Botet | E. Reynaga | L. Morata | L. Soldevila | O. Murillo | E. Benavent | A. Padullés | Francesc Escrihuela-Vidal | L. Albiach
[1] M. Salavert Lletí,et al. Safety and Tolerability of More than Six Days of Tedizolid Treatment , 2020, Antimicrobial Agents and Chemotherapy.
[2] R. Kullar,et al. Retrospective Real-World Evaluation of Outcomes in Patients with Skin and Soft Structure Infections Treated with Tedizolid in an Outpatient Setting , 2020, Infectious Diseases and Therapy.
[3] C. Carvalhaes,et al. Tedizolid in vitro activity against Gram-positive clinical isolates causing bone and joint infections in hospitals in the USA and Europe (2014-17). , 2019, The Journal of antimicrobial chemotherapy.
[4] E. Peters,et al. IWGDF Guideline on the diagnosis and treatment of foot infection in persons with diabetes , 2019 .
[5] Mikhail A. Dziadzko,et al. Correction of Linezolid-Induced Myelotoxicity After Switch to Tedizolid in a Patient Requiring Suppressive Antimicrobial Therapy for Multidrug-Resistant Staphylococcus epidermidis Prosthetic-Joint Infection , 2018, Open forum infectious diseases.
[6] S. Liang,et al. Successful Treatment of Prosthetic Joint Infection Due to Vancomycin-Resistant Enterococci With Tedizolid , 2017, Infectious diseases in clinical practice.
[7] Robin Patel,et al. Activity of Tedizolid in Methicillin-Resistant Staphylococcus epidermidis Experimental Foreign Body-Associated Osteomyelitis , 2016, Antimicrobial Agents and Chemotherapy.
[8] S. Flanagan,et al. Characterization of the haematological profile of 21 days of tedizolid in healthy subjects. , 2016, The Journal of antimicrobial chemotherapy.
[9] Robin Patel,et al. Activity of Tedizolid in Methicillin-Resistant Staphylococcus aureus Experimental Foreign Body-Associated Osteomyelitis , 2016, Antimicrobial Agents and Chemotherapy.
[10] J. Briegel,et al. Decreased Linezolid Serum Concentrations in Three Critically Ill Patients: Clinical Case Studies of a Potential Drug Interaction between Linezolid and Rifampicin , 2016, Pharmacology.
[11] R. Stahlmann,et al. Drug–drug interactions and safety of linezolid, tedizolid, and other oxazolidinones , 2015, Expert opinion on drug metabolism & toxicology.
[12] M. Gilmour,et al. Tedizolid: A Novel Oxazolidinone with Potent Activity Against Multidrug-Resistant Gram-Positive Pathogens , 2015, Drugs.
[13] P. Tulkens,et al. Nonclinical and Pharmacokinetic Assessments To Evaluate the Potential of Tedizolid and Linezolid To Affect Mitochondrial Function , 2014, Antimicrobial Agents and Chemotherapy.
[14] Á. Soriano,et al. Clinical experience with linezolid for the treatment of orthopaedic implant infections. , 2014, The Journal of antimicrobial chemotherapy.
[15] G. Moran,et al. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. , 2014, The Lancet. Infectious diseases.
[16] S. Flanagan,et al. Single- and Multiple-Dose Pharmacokinetics and Absolute Bioavailability of Tedizolid , 2014, Pharmacotherapy.
[17] D. Paterson,et al. Clinical Population Pharmacokinetics and Toxicodynamics of Linezolid , 2014, Antimicrobial Agents and Chemotherapy.
[18] J. Ariza,et al. Linezolid in late-chronic prosthetic joint infection caused by gram-positive bacteria. , 2013, Diagnostic microbiology and infectious disease.
[19] S. Flanagan,et al. In Vitro, In Vivo, and Clinical Studies of Tedizolid To Assess the Potential for Peripheral or Central Monoamine Oxidase Interactions , 2013, Antimicrobial Agents and Chemotherapy.
[20] Anita F. Das,et al. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. , 2013, JAMA.
[21] A. Hanssen,et al. Diagnosis and management of prosthetic joint infection: clinical practice guidelines by the Infectious Diseases Society of America. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[22] F. Pea,et al. Therapeutic drug monitoring may improve safety outcomes of long-term treatment with linezolid in adult patients. , 2012, The Journal of antimicrobial chemotherapy.
[23] R Scott Obach,et al. Unexpected Effect of Rifampin on the Pharmacokinetics of Linezolid: In Silico and In Vitro Approaches to Explain Its Mechanism , 2011, Journal of clinical pharmacology.
[24] Y. Yazdanpanah,et al. Tolerability of prolonged linezolid therapy in bone and joint infection: protective effect of rifampicin on the occurrence of anaemia? , 2010, The Journal of antimicrobial chemotherapy.
[25] Y. Yazdanpanah,et al. Effectiveness and tolerability of prolonged linezolid treatment for chronic osteomyelitis: a retrospective study. , 2006, Clinical therapeutics.
[26] John W. Wilson,et al. Linezolid and serotonergic drug interactions: a retrospective survey. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[27] S. Grau,et al. Linezolid-associated serotonin syndrome: what we can learn from cases reported so far. , 2005, The Journal of antimicrobial chemotherapy.
[28] K. Kümmerer,et al. Linezolid and Rifampin: Drug Interaction Contrary to Expectations? , 2005, Clinical pharmacology and therapeutics.
[29] S. Gerson,et al. Hematologic Effects of Linezolid: Summary of Clinical Experience , 2002, Antimicrobial Agents and Chemotherapy.